Audiological and electrophysiological alterations in HIV-infected individuals subjected or not to antiretroviral therapy

Carregando...
Imagem de Miniatura
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2018
Título da Revista
ISSN da Revista
Título do Volume
Editora
ASSOC BRASILEIRA OTORRINOLARINGOLOGIA & CIRURGIA CERVICOFACIAL
Citação
BRAZILIAN JOURNAL OF OTORHINOLARYNGOLOGY, v.84, n.5, p.574-582, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Introduction: The Human Immunodeficiency Virus (HIV) and infections related to it can affect multiple sites in the hearing system. The use of High Activity Anti-Retroviral Therapy (HAART) can cause side effects such as ototoxicity. Thus, no consistent patterns of hearing impairment in adults with Human Immunodeficiency Virus / Acquired Immune Deficiency Syndrome have been established, and the problems that affect the hearing system of this population warrant further research. Objectives: This study aimed to compare the audiological and electrophysiological data of Human Immunodeficiency Virus-positive patients with and without Acquired Immune Deficiency Syndrome, who were receiving High Activity Anti-Retroviral Therapy, to healthy individuals. Methods: It was a cross-sectional study conducted with 71 subjects (30-48 years old), divided into groups: Research Group I: 16 Human Immunodeficiency Virus-positive individuals without Acquired Immunodeficiency Syndrome (not receiving antiretroviral treatment); Research Group II: 25 Human Immunodeficiency Virus-positive individuals with Acquired Immunodeficiency Syndrome (receiving antiretroviral treatment); Control Group: 30 healthy subjects. All individuals were tested by pure-tone air conduction thresholds at 0.25-8 kHz, extended high frequencies at 9-20 kHz, electrophysiological tests (Auditory Brainstem Response, Middle Latency Responses, Cognitive Potential). Results: Research Group I and Research Group II had higher hearing thresholds in both conventional and high frequency audiometry when compared to the control group, prolonged latency of waves I, III, V and interpeak I-V in Auditory Brainstem Response and prolonged latency of P300 Cognitive Potential. Regarding Middle Latency Responses, there was a decrease in the amplitude of the Pa wave of Research Group II compared to the Research Group I. Conclusions: Both groups with Human Immunodeficiency Virus had higher hearing thresholds when compared to healthy individuals (group exposed to antiretroviral treatment showed the worst hearing threshold) and seemed to have lower neuroelectric transmission speed along the auditory pathway in the brainstem, subcortical and cortical regions. (C) 2018 Associacao Brasileira de Otorrinolaringologia e Cirurgia Cervico-Facial.
Palavras-chave
Acquired immunodeficiency syndrome, Adults, Auditory evoked potentials, Hearing loss, HIV
Referências
  1. ANDERS KH, 1986, AM J PATHOL, V124, P537
  2. BANKAITIS AE, 1995, EAR HEARING, V16, P321, DOI 10.1097/00003446-199506000-00009
  3. Bankaitis Aukse E., 1998, Seminars in Hearing, V19, P177, DOI 10.1055/s-0028-1082967
  4. Bungener C, 1996, PROG NEURO-PSYCHOPH, V20, P1303, DOI 10.1016/S0278-5846(96)00127-3
  5. Campanini A, 2005, Acta Otorhinolaryngol Ital, V25, P30
  6. Castello E, 1998, ANN OTO RHINOL LARYN, V107, P1054, DOI 10.1177/000348949810701210
  7. Castro NM, 2000, REV CLIN ESP, V200, P271
  8. Chandrasekhar SS, 2000, AM J OTOLARYNG, V21, P1, DOI 10.1016/S0196-0709(00)80117-9
  9. Colebunders R, 1998, EUR J CLIN MICROBIOL, V17, P214, DOI 10.1007/BF01691123
  10. DOURNON E, 1988, LANCET, V2, P1297
  11. FEIN G, 1995, ARCH NEUROL-CHICAGO, V52, P1109, DOI 10.1001/archneur.1995.00540350103022
  12. Fokouo JVF, 2015, JAMA OTOLARYNGOL, V141, P436, DOI 10.1001/jamaoto.2015.125
  13. Gurney TA, 2003, OTOLARYNG CLIN N AM, V36, P607, DOI 10.1016/S0030-6665(03)00031-8
  14. Juan K., 2009, AVALIACAO AUDIOLOGIC
  15. KOHAN D, 1988, ANN OTO RHINOL LARYN, V97, P636, DOI 10.1177/000348948809700611
  16. Lin C, 2013, JAMA OTOLARYNGOL, V139, P251, DOI 10.1001/jamaoto.2013.1709
  17. Lloyd LL, 1978, AUDIOMETRIC INTERPRE
  18. Maro II, 2014, EAR HEARING, V35, P306, DOI 10.1097/01.aud.0000439101.07257.ed
  19. Matas Carla Gentile, 2006, Pró-Fono R. Atual. Cient., V18, P171, DOI 10.1590/S0104-56872006000200006
  20. Ministerio da Saude. Coordenacao Nacional DST/AIDS, 1999, J BRAS DOENCAS SEX T, V11, P31
  21. Palacios GC, 2008, INT J PEDIATR OTORHI, V72, P1671, DOI 10.1016/j.ijporl.2008.08.002
  22. PAPPAS DG, 1994, AM J OTOL, V15, P456
  23. Pierelli F, 1996, ACTA NEUROL SCAND, V93, P266
  24. Polich J, 2000, INT J PSYCHOPHYSIOL, V38, P97, DOI 10.1016/S0167-8760(00)00133-1
  25. RAREY KE, 1990, AM J OTOLARYNG, V11, P366, DOI 10.1016/0196-0709(90)90113-A
  26. Reis AC, 2007, EPIDEMIOL SERV SAUDE, V16, P195
  27. Rey D, 2002, CLIN INFECT DIS, V34, P418, DOI 10.1086/324368
  28. Reyes-Contreras L, 2002, ARCH MED RES, V33, P25, DOI 10.1016/S0188-4409(01)00342-3
  29. Serafini G, 1998, Rev Laryngol Otol Rhinol (Bord), V119, P87
  30. Silman S, 1997, AUDITORY DIAGNOSIS P, P44
  31. Silva Aline Covo da, 2007, Pró-Fono R. Atual. Cient., V19, P352, DOI 10.1590/S0104-56872007000400005
  32. Tartar JL, 2004, NEUROREPORT, V15, P1675, DOI 10.1097/01.wnr.0000134992.74181.4b
  33. Thein P, 2014, HEARING RES, V310, P27, DOI 10.1016/j.heares.2014.01.005
  34. Torre P, 2015, JAMA OTOLARYNGOL, V141, P202, DOI 10.1001/jamaoto.2014.3302
  35. UNAIDS, 2010, GLOB REP UNAIDS REP
  36. van der Westhuizen Y, 2013, INT J AUDIOL, V52, P37, DOI 10.3109/14992027.2012.721935
  37. Vieira ABC, 2010, REV MED MINAS GERAIS, V20, P102
  38. Wilkin TJ, 2008, CLIN INFECT DIS, V47, P1580, DOI 10.1086/593311
  39. Williams B, 2001, CLIN INFECT DIS, V33, P2100, DOI 10.1086/324361